In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Grace A JohnsonDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Diego DetrésDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Ondine AtwaDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Jari BulkensDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Samuel GruberDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Manuel E ContrerasDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Alexandra N WuestDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-7337-8619 Varun K NarendraCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8970-5135 Francisco J Sánchez-RiveraDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-8466-8563 Funding
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9MPre-doctoral Training in Fundamental Approaches to Biochemistry and Cell and Molecular BiologyT32GM136540 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Mary Gehring, Michael Laub · 2021 to 2026
$9.5MMutant p53 in Tumorigenesis, Invasion, and MetastasisP01CA291694 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI James J Manfredi · 2025 to 2026
$7.9MRNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer TherapiesR01CA226898 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B, HEMANN, MICHAEL · 2019 to 2023
$2.7MIdentifying and targeting evolutionary trajectories in cancerR01CA233477 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HEMANN, MICHAEL · 2019 to 2023
$1.7MDissecting the mechanism of cyclophosphamide-enhanced antibody efficacyR21AI151827 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HEMANN, MICHAEL · 2020 to 2021
$408kNCI NIH HHS P01 CA291694NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA226898NCI NIH HHS R01 CA233477NIAID NIH HHS R21 AI151827NIGMS NIH HHS T32 GM136540
6 · The paper itselfAbstract
Human genome sequencing efforts in healthy and diseased individuals continue to identify a broad spectrum of genetic variants associated with predisposition, progression, and therapeutic outcomes for diseases like cancer
Identifiers
PMID40060482
PMCPMC11888363
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390